(Q36402296)

English

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

author name string

Daniel J Freeman

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Kevin McDorman

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Selam Ogbagabriel

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Carl Kozlosky

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Bing-Bing Yang

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Sameer Doshi

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Juan Jose Perez-Ruxio

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

William Fanslow

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Charlie Starnes

9

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Robert Radinsky

10

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

publication date

25 July 2012

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Molecular Cancer

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

47

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Pharmacokinetic considerations for new targeted therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

EGFR and cancer prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

The role of amphiregulin in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

30 September 2017

Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

28 June 2018

Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation

1 reference

https://api.crossref.org/works/10.1186%2F1476-4598-11-47

21 January 2018

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

21 September 2018

Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499177

21 September 2018

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22830443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22830443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/22830443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/22830443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules

1 reference

https://pubmed.ncbi.nlm.nih.gov/22830443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1476-4598-11-47

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36402296&oldid=2198837897"